
CLAIMS

What is claimed is:

1. A compound comprising the structure:



wherein

n independently is an integer from about 1 to about 800,

m is independently an integer from about 1 to about 5, and

wherein the Globo H moieties are covalently bound to the KLH moiety(ies) on basic amino acid residues.

2. The compound of claim 1, wherein m is 1 and n is from about 1 to about 150.

3. The compound of claim 1, wherein m is 2 and n is from about 1 to about 300.

4. The compound of claim 1, wherein m is 3 and n is from about 1 to about 450.

5. The compound of claim 1, wherein m is 4 and n is from about 1 to about 600.

6. The compound of claim 1, wherein m is 5 and n is from about 1 to about 750.

7. The compound of claim 1, wherein n is from about 60 to about 100.

8. The compound of claim 1, wherein n is from about 70 to about 90.


9. The compound of claim 1, wherein n is from about 75 to about 80.

14. A therapeutic composition comprising a plurality of Globo H moieties covalently linked to three keyhole limpet hemocyanin (KLH) moieties, wherein the number of Globo H moieties is from about 1 to about 450, expressed as the number of Globo H molecules to a trimeric KLH moiety.

15. A therapeutic composition comprising a plurality of Globo H moieties covalently linked to four keyhole limpet hemocyanin (KLH) moieties, wherein the number of Globo H moieties is from about 1 to about 600, expressed as the number of Globo H molecules to a tetrameric KLH moiety.

16. A therapeutic composition comprising a plurality of Globo H moieties covalently linked to five keyhole limpet hemocyanin (KLH) moieties, wherein the number of Globo H moieties is from about 1 to about 750, expressed as the number of Globo H molecules to a pentameric KLH moiety.

17. A pharmaceutical composition comprising: a compound comprising the structure:



wherein n independently is an integer from about 1 to about 750, and wherein m is independently an integer from about 1 to about 5, and optionally a pharmaceutically acceptable carrier.

18. The composition of claim 17, wherein m is 1 and n is from about 1 to about 150.

19. The composition of claim 17, wherein m is 2 and n is from about 1 to about 300.

46. The pharmaceutical composition of claim 33 formulated for subcutaneous injection.

47. The pharmaceutical composition of claim 33 formulated for intravenous administration.

48. The pharmaceutical composition of claim 33 formulated for intra-muscular administration.

49. Use of the compound according to any one of claims 1 to 10, the therapeutic composition according to anyone of claims 11 to 26 or the pharmaceutical composition according to any one of claims 27 to 48 in the preparation of a medicament for treating cancer in a patient.

~~49.~~50. Use of the pharmaceutical composition according to claim 33 in the preparation of a medicament for ~~A method of~~ treating cancer ~~in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claim 33~~.

~~50.~~51. The ~~method~~ use of claim 49 or claim 50, wherein the cancer is ovarian cancer.

~~51.~~52. The ~~method~~ use of claim 49 or claim 50, wherein the cancer is an epithelial cancer.

~~52.~~53. The ~~method~~ use of claim 49 or claim 50, wherein the cancer is breast cancer.

~~53.~~54. The ~~method~~ use of claim 49 or claim 50, wherein therapeutically effective amount of Globo-H moiety in the ~~composition~~ medicament comprises from about 0.01 μg/kg to about 250 mg/kg.

~~54.~~55. The ~~method~~ use of claim 49 or claim 50, wherein therapeutically effective amount of Globo-H moiety in the ~~composition~~ medicament comprises from about 0.10 μg/kg to about 0.75 μg/kg.

~~55.~~56. The ~~method~~ use of claim 49 or claim 50, wherein therapeutically effective amount of Globo-H-KLH complex in the ~~composition~~ medicament comprises from about 0.01 μg/kg to about 250 mg/kg.

~~56.~~57. The ~~method~~ use of claim 49 or claim 50, wherein therapeutically effective amount of Globo-H-KLH complex in the ~~composition~~ medicament comprises from about 0.60 μg/kg to about 4.50 μg/kg.

58. A method of inducing antibodies in an animal or a human for the purpose of creating monoclonal antibodies ~~for therapeutic or diagnostic uses~~ comprising administering to the animal or human an effective amount of the compound according to any one of claim 1 to 10, the therapeutic composition according to any one of claim 11 to 26 or the pharmaceutical composition according to any one of claims 27 to 48~~composition of claim 49~~.

~~57.~~59. Use of the compound according to any one of claims 1 to 10, the therapeutic composition according to anyone of claims 11 to 26 or the pharmaceutical composition according to any one of claims 27 to 48 in the manufacturing of a preparation for inducing antibodies in an animal or a human for the purpose of creating monoclonal antibodies for therapeutic or diagnostic uses.